Biotech News
-
Voyageur Pharmaceuticals Launches U.S. Iodine Feasibility Study to Establish First Fully Integrated North American Contrast Drug Manufacturing Platform
August 25, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC: VYYRF) (“Voyageur” or the “Corporation”) is pleased…
-
Voyageur Pharmaceuticals Initiates First Commercial Shipments of Barium Contrast Products to Canadian Clinics
August 21, 2025 (Source) — TheNewswire – Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”), a radiology…
-
Voyageur Pharmaceuticals Announces Exercise of Warrants for Gross Proceeds of $1.69 Million
August 19, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”), a company with…
-
Voyageur Advances Frances Creek Barite Project with VAST Engagement for Bulk Sample Permit
August 18, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC: VYYRF) (“Voyageur” or the “Corporation”), is pleased to…
-
DIAGNOS to Extend Stock Warrants Exercise Period
August 15, 2025 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A),…
-
DIAGNOS Announces Extension of Stock Warrants Exercise Period
August 13, 2025 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A),…
-
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p =…
-
DIAGNOS Files FDA Pre-Submission for its CARA System: Strategic Entry into the U.S. Optometry Market with Support from ORA LLC
July 16, 2025 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A),…
-
Voyageur Pharmaceuticals Grants Deferred Share Units and Options and Accelerates Expiry Date of Warrants
July 14, 2025 (Source) — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC: VYYRF) (“Voyageur” or the “Corporation”), a provider…
-
DIAGNOS Welcomes Veteran Optometrist Dr. Barry A. Ginsberg to its Scientific Advisory Board for the United States
June 25, 2025 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A),…
